The role for IGF-1-derived small neuropeptides as a therapeutic target for neurological disorders

Bibliography

• Sara VR, Carlsson-Skwirut C. The role of the insulin-like growth factors in the regulation of brain development. Prog Brain Res 1988;73:87-99
   Google Scholar
• Gluckman PD, Klempt N, Guan J, et al. A role for IGF-1 in the rescue of CNS neurons following hypoxic- ischemic injury. Biochem Biophys Res Commun 1992;182:593-9
   PubMed Web of Science ®Google Scholar
• Adem A, Jossan S, d’Argy R, et al. Insulin-like growth factor 1 (IGF-1) receptors in the human brain: quantitative autoradiographic localization. Brain Res 1989;503:299-303
   PubMedGoogle Scholar
• Drakenberg K, Sara VR, Falkmer S, et al. Identification of IGF-1 receptors in primitive vertebrates. Regul Pept 1993;43:73-81
   Google Scholar
• Sara VR, Hall K. Insulin-like growth factors and their binding proteins. Physiol Rev 1990;70:591-614
   PubMed Web of Science ®Google Scholar
• Beilharz EJ, Russo VC, Butler G, et al. Co-ordinated and cellular specific induction of the components of the IGF/IGFBP axis in the rat brain following hypoxic-ischemic injury. Brain Res Mol Brain Res 1998;59:119-34
   PubMedGoogle Scholar
• Lee WH, Wang GM, Seaman LB, et al. Coordinate IGF-I and IGFBP5 gene expression in perinatal rat brain after hypoxia-ischemia. J Cereb Blood Flow Metab 1996;16:227-36
   PubMed Web of Science ®Google Scholar
• Brywe KG, Mallard C, Gustavsson M, et al. IGF-I neuroprotection in the immature brain after hypoxia-ischemia, involvement of Akt and GSK3beta? Eur J Neurosci 2005;21:1489-502
   PubMedGoogle Scholar
• Cortes-Canteli M, Zamolodchikov D, Ahn HJ, et al. Fibrinogen and altered hemostasis in Alzheimer’s disease. J Alzheimers Dis 2012;32:599-608
   PubMed Web of Science ®Google Scholar
• Guan J, Miller OT, Waugh KM, et al. Insulin-like growth factor-1 improves somatosensory function and reduces the extent of cortical infarction and ongoing neuronal loss after hypoxia-ischemia in rats. Neuroscience 2001;105:299-306
   PubMed Web of Science ®Google Scholar
• Beilharz EJ, Bassett NS, Sirimanne ES, et al. Insulin-like growth factor II is induced during wound repair following hypoxic-ischemic injury in the developing rat brain. Mol Brain Res 1995;29:81-91
   PubMedGoogle Scholar
• Gluckman PD, Ambler GR. Therapeutic use of insulin-like growth factor I: lessons from in vivo animal studies. Acta Paediatr Suppl 1992;383:134-6
   Google Scholar
• Lee WH, Michels KM, Bondy CA. Localization of insulin-like growth factor binding protein-2 messenger RNA during postnatal brain development: correlation with insulin-like growth factors I and II. Neuroscience 1993;53:251-65
   PubMed Web of Science ®Google Scholar
• Yamaguchi F, Itano T, Miyamoto O, et al. Increase of extracellular insulin-like growth factor I (IGF-I) concentration following electrolytical lesion in rat hippocampus. Neurosci Lett 1991;128:273-6
   Google Scholar
• Sonntag WE, Ramsey M, Carter CS. Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging. Ageing Res Rev 2005;4:195-212
   PubMed Web of Science ®Google Scholar
• Guan J, Williams C, Gunning M, et al. The effects of IGF-1 treatment after hypoxic-ischemic brain injury in adult rats. J Cereb Blood Flow Metab 1993;13:609-16
   PubMed Web of Science ®Google Scholar
• Johnston BM, Mallard EC, Williams CE, et al. Insulin-like growth factor-1 is a potent neuronal rescue agent after hypoxic-ischemic injury in fetal lambs. J Clin Invest 1996;97:300-8
   PubMed Web of Science ®Google Scholar
• Guan J, Bennet L, George S, et al. Insulin-like growth factor-1 reduces postischemic white matter injury in fetal sheep. J Cereb Blood Flow Metab 2001;21:493-502
   PubMed Web of Science ®Google Scholar
• Guan J, Thomas GB, Lin H, et al. Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate (GPE) following intravenous infusion in hypoxic-ischemic adult rats. Neuropharmacology 2004;47:892-903
   PubMed Web of Science ®Google Scholar
• Fisher M, Schaebitz W. An overview of acute stroke therapy. Arch Intern Med 2000;160:3196-207
   PubMed Web of Science ®Google Scholar
• Lees KR. Management of acute stroke. Lancet Neurol 2002;1:41-50
   Google Scholar
• Guan J, Gunn AJ, Sirimanne ES, et al. The window of opportunity for neuronal rescue with insulin-like growth factor-1 after hypoxia-ischemia in rats is critically modulated by cerebral temperature during recovery. J Cereb Blood Flow Metab 2000;20:513-19
   Google Scholar
• Pardridge WM. Drug delivery to the brain. J Cereb Blood Flow Metab 1997;17:713-31
   PubMed Web of Science ®Google Scholar
• Liu XF, Fawcett JR, Thorne RG, et al. Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion. Neurosci Lett 2001;308:91-4
   PubMed Web of Science ®Google Scholar
• Saatman KE, Contreras PC, Smith DH, et al. Insulin-like growth factor-1 (IGF-1) improves both neurological motor and cognitive outcome following experimental brain injury. Exp Neurol 1997;147:418-27
   PubMed Web of Science ®Google Scholar
• Hanson LR, Frey WH2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008;9:S5
   PubMed Web of Science ®Google Scholar
• Rosenbloom AL. Mecasermin (recombinant human insulin-like growth factor I). Adv Ther 2009;26:40-54
   PubMed Web of Science ®Google Scholar
• Sara VR, Carlsson Skwirut C, Drakenberg K, et al. Truncated IGF-1 in the CNS. Ann NY Acad Sci 1992;175th:24
   Google Scholar
• Yamamoto H, Murphy LJ. Enzymatic conversion of IGF-I to des(1-3)IGF-I in rat serum and tissues: a further potential site of growth hormone regulation of IGF-I action. J Endocrinol 1995;146:141-8
   Google Scholar
• Yamamoto H, Maake C, Murphy LJ. Enhanced proteolytic activity directed against the N-terminal of IGF-I in diabetic rats. J Endocrinol 1999;162:243-50
   Google Scholar
• Yamamoto H, Murphy LJ. N-terminal truncated insulin-like growth factor-I in human urine. J Clin End Metab 1995;80:1179-83
   Google Scholar
• Sara VR, Carlsson-Sdwirut C, Bergman T, et al. Indentification of Gly-Pre-Glu(GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroaction peptide. Biochem Biophys Res Commun 1989;165:766-71
   PubMed Web of Science ®Google Scholar
• Nilsson-Hakansson L, Civalero I, Zhang X, et al. Effects of IGF-1, truncated IGF-1 and the tripeptide Gly-Pro-Glu on acetylcholine release from parietal cortex of rat brain. Neuroreport 1993;4:1111-14
   PubMed Web of Science ®Google Scholar
• Saura J, Curatolo L, Williams CE, et al. Neuroprotective effects of Gly-Pro-Glu, the N-terminal tripeptide of IGF-1, in the hippocampus in vitro. Neuroreport 1999;10:161-4
   PubMed Web of Science ®Google Scholar
• Bourguignon JP, Gerard A. Role of insulin-like growth factor binding proteins in limitation of IGF-1 degradation into the N-methyl-D-aspartate receptor antagonist GPE: evidence from gonadotropin-releasing hormone secretion in vitro at two developmental stages. Brain Res 1999;847:147-52
   Google Scholar
• Bourguignon JP, Gerard A, Alvarez Gonzalez ML, et al. Acute suppression of gonadotropin-releasing hormone secretion by insulin-like growth factor I and subproducts: an age-dependent endocrine effect. Neuroendocrinology 1993;58:525-30
   Google Scholar
• Alonso De Diego SA, Gutierrez-Rodriguez M, Perez de Vega MJ, et al. The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett 2006;16:3396-400
   Google Scholar
• Guan J, Waldvogel HJ, Faull RL, et al. The effects of the N-terminal tripeptide of insulin-like growth factor- 1, glycine-proline-glutamate in different regions following hypoxic- ischemic brain injury in adult rats. Neuroscience 1999;89:649-59
   Google Scholar
• Sizonenko SV, Sirimanne ES, Gluckman PD, et al. Neuroprotective effects of the N-terminal tripeptide of IGF-1, glycine-proline-glutamate, in the immature rat brain after hypoxic-ischemic injury. Brain Res 2001;922:42-50
   PubMedGoogle Scholar
• Batchelor DC, Lin H, Wen J-Y, et al. Pharmacokinetics of glycine-proline-glutamate, the N-terminal tripeptide of insulin-like growth factor-1, in rats. Anal Biochem 2003;323:156-63
   PubMed Web of Science ®Google Scholar
• Baker AM, Batchelor DC, Thomas GB, et al. Central penetration and stability of N-terminal tripeptide of insulin-like growth factor-I, glycine-proline-glutamate in adult rat. Neuropeptides 2005;39:81-6
   PubMed Web of Science ®Google Scholar
• Fujimura M, Gasche Y, Morita-Fujimura Y, et al. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 1999;842:92-9
   PubMed Web of Science ®Google Scholar
• Planas AM, Sole S, Justicia C. Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis 2001;8:834-46
   PubMed Web of Science ®Google Scholar
• Knapp J, Teschendorf P, Vogel P, et al. Effects of intracerebroventricular application of insulin-like growth factor 1 and its N-terminal tripeptide on cerebral recovery following cardiac arrest in rats. Resuscitation 2013;84:684-9
   Google Scholar
• Finch CE. Neurons, glia, and plasticity in normal brain aging. Adv Gerontol 2002;10:35-9
   Google Scholar
• Wu WW, Oh MM, Disterhoft JF. Age-related biophysical alterations of hippocampal pyramidal neurons: implications for learning and memory. Ageing Res Rev 2002;1:181-207
   PubMed Web of Science ®Google Scholar
• Gladsrone DJ, Black SE, Hakim AM. Toward wisdom from failure- Lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002;33:2123-36
   Google Scholar
• Shapira S, Mathai S, Zhang R, et al. Delayed peripheral administration of the N-terminal tripeptide of IGF-1 (GPE) reduces brain damage following microsphere induced embolic damage in young adult and aged rats. Neurosci Lett 2009;454:53-7
   Google Scholar
• Guan J, Krishnamurthi R, Waldvogel HJ, et al. N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats. Brain Res 2000;859:286-92
   Google Scholar
• Krishnamurthi R, Stott S, Maingay M, et al. N-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats. Neuroreport 2004;15:1601-4
   Google Scholar
• Olsson M, Nikkhah G, Bentlage C, et al. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 1995;15:3863-75
   PubMed Web of Science ®Google Scholar
• Minelli A, Conte C, Cacciatore I, et al. Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L-dopa in a Parkinson’s animal model. Amino Acids 2012;43:1359-67
   PubMed Web of Science ®Google Scholar
• Alexi T, Hughes PE, van Roon-Mom WM, et al. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington’s disease. Exp Neurol 1999;159:84-97
   Google Scholar
• Burgos-Ramos E, Martos-Moreno GA, Lopez MG, et al. The N-terminal tripeptide of insulin-like growth factor-I protects against beta-amyloid-induced somatostatin depletion by calcium and glycogen synthase kinase 3 beta modulation. J Neurochem 2009;109:360-70
   Google Scholar
• Park SE, Lawson M, Dantzer R, et al. Insulin-like growth factor-I peptides act centrally to decrease depression-like behavior of mice treated intraperitoneally with lipopolysaccharide. J Neuroinflammation 2011;8:179
   Google Scholar
• Harris PWR, Brimble MA, Muir VJ, et al. Synthesis of proline-modified analogues of the neuroprotective agent glucyl-l-prolyl-glutamic acid (GPE). Tetrahedorn 2005;61:10018-35
   Google Scholar
• Bickerdike MJ, Thomas GB, Batchelor DC, et al. NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke. J Neurol Sci 2009;278:85-90
   Google Scholar
• Zhao X, Liu SJ, Zhang J, et al. Combining insulin-like growth factor derivatives plus caffeinol produces robust neuroprotection after stroke in rats. Stroke 2005;36:129-34
   PubMedGoogle Scholar
• Svedin P, Guan J, Mathai S, et al. Delayed peripheral administration of a GPE analogue induces astrogliosis and angiogenesis and reduces inflammation and brain injury following hypoxia-ischemia in the neonatal rat. Dev Neurosci 2007;29:393-402
   PubMed Web of Science ®Google Scholar
• Lu XC, Chen RW, Yao C, et al. NNZ-2566, a glypromate analog, improves functional recovery and attenuates apoptosis and inflammation in a rat model of penetrating ballistic-type brain injury. J Neurotrauma 2009;26:141-54
   Google Scholar
• Lu XC, Si Y, Williams AJ, et al. NNZ-2566, a glypromate analog, attenuates brain ischemia-induced non-convulsive seizures in rats. J Cereb Blood Flow Metab 2009;29:1924-32
   Google Scholar
• Wei HH, Lu XC, Shear DA, et al. NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats. J Neuroinflammation 2009;6:19
   PubMed Web of Science ®Google Scholar
• Cartagena CM, Phillips KL, Williams GL, et al. Mechanism of action for NNZ-2566 anti-inflammatory effects following PBBI involves upregulation of immunomodulator ATF3. Neuromolecular Med 2013;15:504-14
   Google Scholar
• Samonina G, Ashmarin I, Lyapina L. Glyproline peptide family: review on bioactivity and possible origins. Pathophysiology 2002;8:229-34
   PubMedGoogle Scholar
• Baker AM. Glycine-Proline-Glutamate (GPE): A Neural Rescue Agent for Acute and Chronic Brain Diseases in Liggins Institute. The University of Auckland; Auckland: 2007. p. 180
   Google Scholar
• Kessler AH. Conformation and biological activity of cyclic peptides. Chem Int Ed Engl 1982;21:512-22
   Web of Science ®Google Scholar
• Trotter NS, Brimble MA, Harris PW, et al. Synthesis and neuroprotective activity of analogues of glycyl-L-prolyl-L-glutamic acid (GPE) modified at the alpha-carboxylic acid. Bioorg Med Chem 2005;13:501-17
   PubMed Web of Science ®Google Scholar
• Guan J, Mathai S, Harris AP, et al. Peripheral administration of a novel diketopiperazine, NNZ 2591, prevents brain injury and improves somatosensory-motor function following hypoxia-ischemia in adult rats. Neuropharmacology 2007;53:749-62
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Transnasal and intraventricular delivery of drugs. In: Pardridge WM, editor. Peptide drug delivery to the brain. Raven Press; NY, USA: 1991. p. 99-122
   Google Scholar
• Endrenyi L. Drug distribution. In: Kalant H, Roschlau WHE, editors. Principles of medical pharmacology. Oxford University Press; NY, USA: 1998. p. 28-37
   Google Scholar
• Krishnamurthi R, Mathai S, Kim H, et al. A novel diketopiperazine improves functional recovery given after the onset of 6-OHDA induced motor deficit in rats Brit J Pharmacol. 2008;156:662-72
   Google Scholar
• Guan J, Zhang R, Dale-Gandar L, et al. NNZ-2591, a novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat. Behav Brain Res 2010;210(2):221-8
   PubMed Web of Science ®Google Scholar
• Guan J, Gluckman PD. IGF-1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions. Br J Pharmacol 2009;157:881-91
   Google Scholar
• Riikonen R. Insulin-like growth factor delivery across the blood-brain barrier. Potential use of IGF-1 as a drug in child neurology. Chemotherapy 2006;52:279-81
   Google Scholar
• Uchiyama Y, Maxson MM, Sawada T, et al. Phospholipid mediated plasticity in exocytosis observed in PC12 cells. Brain Res 2007;1151:46-54
   PubMed Web of Science ®Google Scholar
• Guan J, Gluckman P, Yang P, et al. Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1. Sci Rep 2014;4:4388
   PubMed Web of Science ®Google Scholar